Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Nov;101(11):2455-61.
doi: 10.1111/j.1349-7006.2010.01689.x.

Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin

Toshiaki Takahashi  1 , Eishin Hoshi, Masakazu Takagi, Noriyuki Katsumata, Masaaki Kawahara, Kenji Eguchi
Affiliations
Clinical Trial

Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin

Toshiaki Takahashi et al. Cancer Sci. 2010 Nov.

Abstract

Aprepitant is a new neurokinin-1 (NK(1) ) receptor antagonist developed as a treatment for chemotherapy-induced nausea and vomiting (CINV). To evaluate the efficacy and safety of aprepitant used in combination with standard therapy (granisetron and dexamethasone), we conducted a multicenter, phase II, placebo-controlled, double-blind, randomized study in Japanese cancer patients who received cancer chemotherapy including cisplatin (≥70mg/m(2) ). Aprepitant was administered for 5days. A total of 453 patients were enrolled. In the three study groups, (i) standard therapy, (ii) aprepitant 40/25mg (40mg on day 1 and 25mg on days 2-5) and (iii) aprepitant 125/80mg (125mg on day 1 and 80mg on days 2-5), the percentage of patients with complete response (no emesis and no rescue therapy) was 50.3% (75/149 subjects), 66.4% (95/143 subjects) and 70.5% (103/146 subjects), respectively. This shows that efficacy was significantly higher in the aprepitant 40/25mg and 125/80mg groups than in the standard therapy group (χ(2) test [closed testing procedure]: P=0.0053 and P=0.0004, respectively) and highest in the aprepitant 125/80mg group. The delayed phase efficacy (days 2-5) was similar to the overall phase efficacy (days 1-5), indicating that aprepitant is effective in the delayed phase when standard therapy is not very effective. In terms of safety, aprepitant was generally well tolerated in Japanese cancer patients. (ClinicalTrials.gov number, NCT00212602.)

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow chart. FAS, full analysis set.
Figure 2
Figure 2
Percentage of patients with a complete response (no emesis and no rescue therapy) in the overall phase (days–5) of aprepitant treatment. *P < 0.001 versus standard therapy group. **P < 0.01 versus standard therapy group.
Figure 3
Figure 3
Percentage of patients with a complete response (no emesis and no rescue therapy) in the acute phase (day 1) and the delayed phase (days 2–5). *P < 0.001 versus standard therapy group. **P < 0.01 versus standard therapy group.
See this image and copyright information in PMC

Comment in

References

    1. Grunberg SM, Hesketh PJ. Control of chemotherapy‐induced emesis. N Engl J Med 1993; 329: 1790–6. - PubMed
    1. Bender CM, McDaniel RW, Murphy‐Ende K et al. Chemotherapy‐induced nausea and vomiting. Clin J Oncol Nurs 2002; 6: 94–102. - PubMed
    1. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy‐induced delayed emesis. Drugs 1996; 52: 639–48. - PubMed
    1. Kris MG, Cubeddu LX, Gralla RJ et al. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin Cancer 1996; 78: 2193–8. - PubMed
    1. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence‐based, clinical practice guidelines. J Clin Oncol 1999; 17: 2971–94. Erratum in: J Clin Oncol 1999; 17: 3860. J Clin Oncol 2000; 18: 3064. - PubMed

Publication types

MeSH terms

Associated data